{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
terlipressin
to a specific field?
There is one exact (name or code) match for terlipressin
Status:
US Approved Rx
(2022)
Source:
NDA022231
(2022)
Source URL:
First approved in 2022
Source:
NDA022231
Source URL:
Class:
PROTEIN
Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
Showing 1 - 7 of 7 results
Status:
US Approved Rx
(2022)
Source:
NDA022231
(2022)
Source URL:
First approved in 2022
Source:
NDA022231
Source URL:
Class:
PROTEIN
Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
Status:
US Previously Marketed
Source:
DIAPID by NOVARTIS
(1970)
Source URL:
First approved in 1970
Source:
DIAPID by NOVARTIS
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Lypressin is synthetic analog of porcine antidiuretic hormone vasopressin. Itis a cyclic nonapeptide that differs from Arg-vasopressin by one amino acid, containing Lys at residue 8 instead of Arg. Lypressin-containing nasal spray was used to treat diabetes insipidus, but its marketing by Sandoz (Novartis) was discontinued.
Status:
US Approved Rx
(2022)
Source:
NDA022231
(2022)
Source URL:
First approved in 2022
Source:
NDA022231
Source URL:
Class:
PROTEIN
Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
Status:
US Approved Rx
(2022)
Source:
NDA022231
(2022)
Source URL:
First approved in 2022
Source:
NDA022231
Source URL:
Class:
PROTEIN
Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
![Structure of ALTERNATIVE DEFINITION for [TERLIPRESSIN ACETATE]](/img/796016e9-26d0-fd20-232d-2a3c5a39869c.svg?size=200&context=prixskrupg)
![Structure of ALTERNATIVE DEFINITION for [TERLIPRESSIN]](/img/d5dc1b58-d995-8d5d-af96-f0b83753d7c6.svg?size=200&context=prixskrupg)
![Structure of ALTERNATIVE DEFINITION for [TERLIPRESSIN ACETATE ANHYDROUS]](/img/19532c80-781b-fe2a-9a53-4a87f91b3de7.svg?size=200&context=prixskrupg)